Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection

BackgroundCeftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed in the United States and China for use in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI). However, the cost-effectiveness of CAZ-AVI is unknown in China. This study ai...

Full description

Bibliographic Details
Main Authors: Wenqiang Kong, Xueting Yang, Yunfeng Shu, Shiqin Li, Bihui Song, Kun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Public Health
Subjects:
ceftazidime-avibactam
polymyxin B
cost-effectiveness
carbapenem-resistant K. pneumoniae
bloodstream infection
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2023.1118307/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2023.1118307/full

Similar Items